• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Moderna, Inc. - Common Stock (NQ:MRNA)

225.00 +28.00 (+14.21%)
Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Moderna, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
Moderna Adds Chief Operating Officer Role as Company Expands into Oncology
September 30, 2026
Juan Andres to Return to Moderna as Chief Operating Officer Jerh Collins to Retire Following Four Years of Leadership at Moderna 
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026
September 21, 2026
Phase 3 data for intismeran autogene in the adjuvant treatment of patients with resected stage IIB-IV melanoma selected for presentation at a Presidential Symposium Moderna to host an investor event... 
From Moderna, Inc.
Via ACCESS Newswire
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
September 15, 2026
EQNX::TICKER_START (NYSE:NNVC),(NASDAQ:GILD),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:BNTX) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
September 15, 2026
A Growing Global Threat From Emerging Viruses Is Fueling Urgent Demand For New Treatments And Creating A Potentially Massive Market For Innovative Antiviral Developers 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Moderna to Present at Upcoming Conferences in September 2026
September 01, 2026
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes
August 28, 2026
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines
August 27, 2026
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes
August 27, 2026
From Moderna, Inc.
Via ACCESS Newswire
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
August 26, 2026
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:BNTX),(NYSE:AZN),(NASDAQ:MRNA),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
August 26, 2026
A New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision Oncology 
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
August 05, 2026
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus
August 04, 2026
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates
July 31, 2026
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
July 16, 2026
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
July 09, 2026
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Appoints Michael McDonnell to Board of Directors
July 08, 2026
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Science Day Highlights Expanding Potential of mRNA Platform
June 25, 2026
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine
June 18, 2026
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna to Host Investor Event - Science Day
June 17, 2026
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028
June 16, 2026
From Moderna, Inc.
Via ACCESS Newswire
News headline image
Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
June 08, 2026
Via ACCESS Newswire
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
June 03, 2026
Via Investor Brand Network
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation
June 03, 2026
Via Investor Brand Network
Topics Artificial Intelligence Intellectual Property
News headline image
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
June 03, 2026
From BioMedWire
Via GlobeNewswire
News headline image
Moderna to Present at Upcoming Conference in June 2026
June 02, 2026
Via ACCESS Newswire
News headline image
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
June 01, 2026
Via ACCESS Newswire
News headline image
Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
June 01, 2026
Via ACCESS Newswire
News headline image
Moderna Recognized by TIME as One of the World's Most Impactful Companies
May 12, 2026
Via ACCESS Newswire
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
May 11, 2026
Via Investor Brand Network
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Targets CNS Drug Delivery Opportunity as Brain Therapeutics Innovation Accelerates
May 11, 2026
Via Investor Brand Network
Topics Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap